Epic Sciences

Press Releases

09.12.2018

Epic Sciences Announces Completion of $52 Million Series E Financing

Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR).

09.04.2018

Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer

Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer.

06.28.2018

Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy

05.22.2018

Epic Sciences Presents Single Cell Genomics Data at 10th DIA China Annual Meeting

New data demonstrates the detection of tumor mutational burden and chromosomal instability in single circulating tumor cells to develop cancer diagnostic tests for guiding immuno-oncology clinical development and decision-making.

05.16.2018

Epic Sciences and Its Collaborators to Present New Data at ASCO 2018

New data validates clinical utility of commercially-available Oncotype DX® AR-V7 Nucleus Detect™ test and additional tests under development for predictive medicine

More Press Releases

In the News

07.07.2016

Genomic Health to market Epic Sciences’ AR-V7 liquid biopsy test.

New York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

07.06.2016

Test aids prostate cancer treatment.

New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.

06.14.2016

Guest Commentary: Back to cancer’s drawing board.

By Murali Prahalad of Epic Sciences — A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.

06.09.2016

Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.

01.28.2016

Epic, Avera ink deal to use liquid biopsy platform in clinical studies.

New York, GenomeWeb — Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

More News